Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Creative Biolabs provides Non-Viral CAR Engineering Platforms to address key challenges in engineered immune cell development, including the complexity of viral vector manufacturing, lengthy development timelines, integration-related safety concerns, and the need for rapid functional evaluation of CAR constructs. This platform enables accelerated development of CAR-T, CAR-NK, and other engineered immune cell products through advanced mRNA delivery technologies, non-integrating nucleic acid engineering, transient expression systems, and streamlined cell engineering workflows. By leveraging flexible, virus-free approaches to CAR expression, Creative Biolabs supports efficient construct screening, rapid proof-of-concept studies, and safer cell engineering strategies for research and translational applications.
Non-viral CAR engineering has emerged as an important alternative approach for developing engineered immune cell therapies. Recent research demonstrates that transient CAR expression strategies can enable rapid cell manufacturing, reduce development complexity, and facilitate efficient screening of CAR designs during early-stage development. Published studies have shown successful implementation of transient CAR expression using mRNA-based approaches, non-integrating nucleic acid systems, and advanced delivery technologies across multiple immune cell types. These findings support the growing role of non-viral platforms as valuable tools for cell therapy research and preclinical development.
Fig.1 General introduction to different gene transfer strategies.1
Creative Biolabs provides non-viral CAR engineering solutions designed to support early-stage discovery, proof-of-concept studies, and translational research. By enabling the rapid generation of transiently engineered CAR-expressing immune cells, this flexible platform allows researchers to efficiently screen antigen-binding domains, signaling architectures, and expression constructs before committing to long-term development strategies. Because it bypasses permanent genomic integration, the system minimizes safety concerns associated with stable modifications while offering an ideal, highly adaptable environment for exploratory studies and iterative optimization.
The platform provides robust modification capabilities across diverse immune cell types, including primary T cells, NK cells, monocyte-derived cells, and stem cell-derived immune effectors. To thoroughly validate these candidates, Creative Biolabs offers an array of functional characterization services. Clients can leverage precise analytical approaches such as CAR expression profiling, cytotoxicity assessments, cytokine secretion analyses, target-cell killing studies, and persistence evaluations.
Discover How We Can Help - Request a Consultation.
Creative Biolabs offers non-viral CAR expression platforms leveraging optimized mRNA, extended-duration circular RNA, self-amplifying RNA, and non-integrating DNA to enable transient expression without genomic integration. Facilitated by lipid nanoparticle-mediated delivery, these technologies support construct screening, process development, and safety-focused research. The platform is backed by robust analytical services, including flow cytometry, expression kinetics, and cytotoxicity assays, ensuring precise functional characterization and optimization to accelerate next-generation CAR immunotherapies.
To proceed with the project, clients need to provide CAR sequences, plasmid or expression cassette details, target antigen information and research goals. You should also specify immune cells, cell lines or preferred cell sources, as well as experimental endpoints and analytical parameters.
You will obtain full deliverables covering CAR expression and transfection efficiency reports, functional assay data and summaries, flow cytometry and immune phenotyping results, cytotoxicity assessment reports, as well as technical guidance for further development.
Enables rapid, integration-free CAR expression through optimized mRNA-LNP delivery systems, supporting transient immune cell engineering, flexible CAR screening, and controlled therapeutic development with enhanced delivery efficiency and expression performance.
Learn More →Utilizes self-amplifying RNA and LNP technologies to achieve prolonged CAR expression with reduced dosing requirements, enabling enhanced immune cell programming, durable functional activity, and innovative next-generation cell therapy development.
Learn More →Employs circular RNA-based LNP delivery to achieve high-yield and stable CAR protein production, supporting improved expression persistence, efficient immune cell modification, and advanced non-integrating CAR engineering strategies.
Learn More →This platform leverages high-capacity eukaryotic DNA transposon machinery to achieve efficient non-viral insertion of CAR coding sequences into cell genomes. It sustains long-term stable transgene expression, supports flexible loading of large-size genetic payloads, and enables scalable industrial manufacturing of next-generation CAR-T and other engineered immune cell therapeutics.
Learn More →Built upon optimized synthetic transposon components belonging to the Tc1/mariner superfamily, the system mediates durable CAR gene integration completely independent of viral vectors. It delivers cost-efficient, scalable, and highly versatile technical solutions for CAR-T research and the preparation of long-acting genetically modified therapeutic immune cells.
Learn More →Provides advanced non-viral DNA platforms using minicircle and nanoplasmid vectors to support efficient CAR gene delivery, reduced genomic risk, and optimized development of engineered immune cell therapies.
Learn More →Utilizes polymeric and hybrid nanoparticle systems for customizable CAR cargo delivery, enabling improved cellular uptake, controlled release, enhanced stability, and versatile non-viral engineering approaches.
Learn More →Harnesses exosome and extracellular vesicle technologies for natural cargo delivery, supporting biocompatible CAR transfer, targeted cellular communication, and innovative approaches for next-generation cell therapy engineering.
Learn More →Q: Why choose a non-viral CAR expression strategy?
A: Non-viral approaches can simplify development workflows, support rapid construct evaluation, and avoid permanent genomic integration. They are particularly valuable for early-stage screening and proof-of-concept studies.
Q: Which immune cell types can be engineered using these platforms?
A: Our platforms can support multiple immune cell formats, including primary T cells, NK cells, stem cell-derived immune cells, and other research-relevant cell populations. Contact our team to discuss your specific cell type requirements.
Q: How long does transient CAR expression typically last?
A: Expression duration depends on the delivery platform, cell type, and construct design. Project-specific optimization can be performed to achieve desired expression profiles.
Q: How do non-viral approaches compare with stable expression systems?
A: Transient platforms are often preferred for rapid screening, early feasibility studies, and flexible CAR optimization. Stable expression systems may be considered during later-stage development when long-term expression is required. Our team can help determine the most suitable strategy for your objectives.
Creative Biolabs provides Non-Viral CAR Engineering Platforms that support rapid CAR design evaluation, flexible immune cell engineering, functional characterization, and preclinical research. Through advanced RNA-based, non-integrating nucleic acid, and lipid-mediated delivery technologies, we help accelerate cell therapy development while maintaining project flexibility and efficiency. Whether you are evaluating new CAR constructs, exploring non-integrating engineering strategies, or advancing a preclinical cell therapy program, Creative Biolabs is ready to support your project. Feel free to contact us if you need additional information or technical support.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
